Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 240

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity

Open access
Cowan, Stephanie, Lim, Siew, Alycia, Chelsea, Pirotta, Stephanie, Thomson, Rebecca, Gibson-Helm, Melanie, Blackmore, Rebecca, Naderpoor, Negar, Bennett, Christie, Ee, Carolyn, Rao, Vibhuti, Mousa, Aya, Alesi, Simon, Moran, Lisa · 2023 · BMC Endocrine Disorders

Abstract

Polycystic ovary syndrome (PCOS) is a common condition affecting reproductive-aged women with reproductive, metabolic and psychological consequences. Weight and lifestyle (diet, physical activity and behavioural) management are first-line therapy in international evidence-based guidelines for PCOS. While these recommend following population-level diet and physical activity guidelines, there is ongoing interest and research in the potential benefit of including psychological and sleep interventions, as well as a range of traditional, complimentary and integrative medicine (TCIM) approaches, for optimal management of PCOS. There is limited evidence to recommend a specific diet composition for PCOS with approaches including modifying protein, carbohydrate or fat quality or quantity generally having similar effects on the presentations of PCOS. With regards to physical activity, promising evidence supports the provision of vigorous aerobic exercise, which has been shown to improve body composition, cardiorespiratory fitness and insulin resistance. Psychological and sleep interventions are also important considerations, with women displaying poor emotional wellbeing and higher rates of clinical and subclinical sleep disturbance, potentially limiting their ability to make positive lifestyle change. While optimising sleep and emotional wellbeing may aid symptom management in PCOS, research exploring the efficacy of clinical interventions is lacking. Uptake of TCIM approaches, in particular supplement and herbal medicine use, by women with PCOS is growing. However, there is currently insufficient evidence to support integration into routine clinical practice. Research investigating inositol supplementation have produced the most promising findings, showing improved metabolic profiles and reduced hyperandrogenism. Findings for other supplements, herbal medicines, acupuncture and yoga is so far inconsistent, and to reduce heterogeneity more research in specific PCOS populations, (e.g. defined age and BMI ranges) and consistent approaches to intervention delivery, duration and comparators are needed. While there are a range of lifestyle components in addition to population-recommendations for diet and physical activity of potential benefit in PCOS, robust clinical trials are warranted to expand the relatively limited evidence-base regarding holistic lifestyle management. With consumer interest in holistic healthcare rising, healthcare providers will be required to broaden their knowledge pertaining to how these therapies can be safely and appropriately utilised as adjuncts to conventional medical management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12902-022-01208-y

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 96 references

Research works printed but not linked: 201

  1. ESHRE TR, Group A-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. · DOI · Paper page
  2. Bahri Khomami M, Moran LJ, Kenny L, Grieger JA, Myers J, Poston L, et al. Lifestyle and pregnancy complications in polycystic ovary syndrome: The SCOPE cohort study. Clin Endocrinol. 2019;90(6):814–21. · DOI
  3. Kakoly N, Khomami M, Joham A, Cooray S, Misso M, Norman R, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018;24(4):455–67. · DOI · Paper page
  4. Barry JA. Exploration of biological causes of psychological problems in polycystic ovary syndrome (PCOS). 2011. City Univerity London (thesis) doi: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.544446
  5. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777–84. · DOI · Paper page
  6. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(2):812–9. · DOI · Paper page
  7. Farid NR, Diamanti-Kandarakis E. Diagnosis and Management of Polycystic Ovary Syndrome: New York. United States: Springer; 2009. · DOI
  8. Moran C, Garcia-Hernandez E, Barahona E, Gonzalez S, Bermudez JA. Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome. Fertil Steril. 2003;80(6):1466–72. · DOI
  9. Tay CT, Moran LJ, Harrison CL, Brown WJ, Joham AE. Physical activity and sedentary behaviour in women with and without polycystic ovary syndrome: An Australian population-based cross-sectional study. Clin Endocrinol. 2020;93(2):154–62. · DOI
  10. Checkland K, Harrison S, McDonald R, Grant S, Campbell S, Guthrie B. Biomedicine, holism and general medical practice: responses to the 2004 General Practitioner contract. Sociol Health Illness. 2008;30(5):788–803. · DOI
  11. Thomas H, Mitchell G, Rich J, Best M. Definition of whole person care in general practice in the English language literature: a systematic review. BMJ Open. 2018;8(12):e023758. · DOI
  12. Collins A, de Iongh A. Independent Commission on Whole Person Care for the UK Labour Party: British Medical Journal Publishing Group; 2014. · doi:10.1136/bmj.g2136
  13. Primary Health Care Advisory Group, Department of Health. Better Outcomes for People with Chronic and Complex Health Conditions. Canberra: Commonwealth of Australia; 2015.
  14. Ferrante JM, Balasubramanian BA, Hudson SV, Crabtree BF. Principles of the patient-centered medical home and preventive services delivery. Ann Fam Med. 2010;8(2):108–16. · DOI · Paper page
  15. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075–91. · DOI · Paper page
  16. Pastoor H, Timman R, de Klerk C, W MB, Laan ET, Laven JS. Sexual function in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod BioMed Online. 2018;37(6):750–60. · DOI
  17. Pastore LM, Patrie JT, Morris WL, Dalal P, Bray MJ. Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women. J Psychosom Res. 2011;71(4):270–6. · DOI
  18. Smith CA, Bateson DJ, Weisberg E. A survey describing the use of complementary therapies and medicines by women attending a family planning clinic. BMC Complement Altern Med. 2013;13(1):1–8. · DOI
  19. Sibbritt DW, Adams J, Young AF. A longitudinal analysis of mid-age women's use of complementary and alternative medicine (CAM) in Australia, 1996–1998. Women Health. 2005;40(4):41–56. · DOI
  20. Gollschewski S, Anderson D, Skerman H, Lyons-Wall P. Associations between the use of complementary and alternative medications and demographic, health and lifestyle factors in mid-life Australian women. Climacteric. 2005;8(3):271–8. · DOI
  21. Barnes LAJ, Barclay L, McCaffery K, Aslani P. Complementary medicine products used in pregnancy and lactation and an examination of the information sources accessed pertaining to maternal health literacy: a systematic review of qualitative studies. BMC Complement Altern Med. 2018;18(1):229. · DOI
  22. van Velden D. The bio-psycho-social approach to health and disease. SADJ. 2003;58(5):191–6.
  23. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3:CD007506.
  24. Haqq L, McFarlane J, Dieberg G, Smart N. The Effect of Lifestyle Intervention on Body Composition, Glycemic Control, and Cardiorespiratory Fitness in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis. Int J Sport Nutr Exerc Metab. 2015;25(6):533–40. · DOI · Paper page
  25. Abdolahian S, Tehrani FR, Amiri M, Ghodsi D, Yarandi RB, Jafari M, et al. Effect of lifestyle modifications on anthropometric, clinical, and biochemical parameters in adolescent girls with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Endocr Disord. 2020;20(1):71. · DOI
  26. Ujvari D, Hulchiy M, Calaby A, Nybacka Å, Byström B, Hirschberg AL. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome. Hum Reprod. 2014;29(7):1526–35. · DOI · Paper page
  27. Oberg E, Gidlöf S, Jakson I, Mitsell M, Tollet Egnell P, Hirschberg AL. Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention-A randomized controlled trial. Clin Endocrinol. 2019;90(3):468–78. · DOI
  28. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84(4):1470–4.
  29. Tolino A, Gambardella V, Caccavale C, D'Ettore A, Giannotti F, D'Antò V, et al. Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2005;119(1):87–93. · DOI · Paper page
  30. Lass N, Kleber M, Winkel K, Wunsch R, Reinehr T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab. 2011;96(11):3533–40. · DOI · Paper page
  31. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003;18(9):1928–32. · DOI · Paper page
  32. Pasquali R, Gambineri A, Cavazza C, Ibarra Gasparini D, Ciampaglia W, Cognigni GE, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011;164(1):53–60. · DOI
  33. Kazemi M, Hadi A, Pierson RA, Lujan ME, Zello GA, Chilibeck PD. Effects of Dietary Glycemic Index and Glycemic Load on Cardiometabolic and Reproductive Profiles in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Adv Nutr. 2020;12(1):161–78. · DOI
  34. Foroozanfard F, Rafiei H, Samimi M, Gilasi HR, Gorjizadeh R, Heidar Z, et al. The effects of dietary approaches to stop hypertension diet on weight loss, anti-Müllerian hormone and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial. Clin Endocrinol. 2017;87(1):51–8. · DOI · Paper page
  35. Ebrahimi-Mamaghani M, Saghafi-Asl M, Pirouzpanah S, Asghari-Jafarabadi M. Effects of raw red onion consumption on metabolic features in overweight or obese women with polycystic ovary syndrome: A randomized controlled clinical trial. J Obstet Gynaecol Res. 2014;40(4):1067–76. · DOI
  36. Karamali M, Kashanian M, Alaeinasab S, Asemi Z. The effect of dietary soy intake on weight loss, glycaemic control, lipid profiles and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: a randomised clinical trial. J Hum Nutr Diet. 2018;31(4):533–43. · DOI · Paper page
  37. Turner-McGrievy GM, Davidson CR, Wingard EE, Billings DL. Low glycemic index vegan or low-calorie weight loss diets for women with polycystic ovary syndrome: a randomized controlled feasibility study. Nutr Res. 2014;34(6):552–8. · DOI
  38. Abedini M, Ghasemi-Tehrani H, Tarrahi M, Amani R. The effect of concentrated pomegranate juice consumption on risk factors of cardiovascular diseases in women with polycystic ovary syndrome: A randomized controlled trial. Phytother Res. 2020;35:442–51. · DOI
  39. Haidari F, Banaei-Jahromi N, Zakerkish M, Ahmadi K. The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial. Nutr J. 2020;19(1):8. · DOI
  40. Kazemi M, McBreairty LE, Zello GA, Pierson RA, Gordon JJ, Serrao SB, et al. A pulse-based diet and the Therapeutic Lifestyle Changes diet in combination with health counseling and exercise improve health-related quality of life in women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. J Psychosom Obstet Gynecol. 2020;41(2):144–53. · DOI · Paper page
  41. Phy JL, Pohlmeier AM, Cooper JA, Watkins P, Spallholz J, Harris KS, et al. Low Starch/Low Dairy Diet Results in Successful Treatment of Obesity and Co-Morbidities Linked to Polycystic Ovary Syndrome (PCOS). J Obes Weight Loss Ther. 2015;5(2):259.
  42. Pohlmeier AM, Phy JL, Watkins P, Boylan M, Spallholz J, Harris KS, et al. Effect of a low-starch/low-dairy diet on fat oxidation in overweight and obese women with polycystic ovary syndrome. Applied physiology, nutrition, and metabolism =. Physiol Appl Nutr Metab. 2014;39(11):1237–44. · DOI · Paper page
  43. Shishehgar F, Mirmiran P, Rahmati M, Tohidi M, Ramezani TF. Does a restricted energy low glycemic index diet have a different effect on overweight women with or without polycystic ovary syndrome? BMC Endocr Disord. 2019;19(1):93. · DOI · Paper page
  44. Szczuko M, Zapałowska-Chwyć M, Drozd A, Maciejewska D, Starczewski A, Wysokiński P, et al. Changes in the IGF-1 and TNF-α synthesis pathways before and after three-month reduction diet with low glicemic index in women with PCOS. Ginekol Pol. 2018;89(6):295–303. · DOI · Paper page
  45. Hoover SE, Gower BA, Cedillo YE, Chandler-Laney PC, Deemer SE, Goss AM. Changes in Ghrelin and Glucagon following a Low Glycemic Load Diet in Women with PCOS. J Clin Endocrinol Metab. 2021;106(5):e2151–e61. · DOI
  46. Ganie MA, Sahar T, Rashid A, Wani IA, Nisar S, Sathyapalan T, et al. Comparative Evaluation of Biomarkers of Inflammation Among Indian Women With Polycystic Ovary Syndrome (PCOS) Consuming Vegetarian vs. Non-vegetarian Diet. Front Endocrinol. 2019;10:699. · DOI
  47. McBreairty LE, Kazemi M, Chilibeck PD, Gordon JJ, Chizen DR, Zello GA. Effect of a pulse-based diet and aerobic exercise on bone measures and body composition in women with polycystic ovary syndrome: A randomized controlled trial. Bone Rep. 2020;12:100248. · DOI
  48. Lujan ME, Brooks ED, Kepley AL, Chizen DR, Pierson RA, Peppin AK. Grid analysis improves reliability in follicle counts made by ultrasonography in women with polycystic ovary syndrome. Ultrasound Med Biol. 2010;36(5):712–8. · DOI
  49. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001;16(6):1255–60. · DOI · Paper page
  50. Katcher HI, Kunselman AR, Dmitrovic R, Demers LM, Gnatuk CL, Kris-Etherton PM, et al. Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome. Fertil Steril. 2009;91(4):1175–82. · DOI
  51. McBreairty LE, Chilibeck PD, Gordon JJ, Chizen DR, Zello GA. Polycystic ovary syndrome is a risk factor for sarcopenic obesity: a case control study. BMC Endocr Disord. 2019;19(1):70. · DOI
  52. Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. Am J Clin Nutr. 2007;85(3):688–94. · DOI
  53. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril. 2004;81(3):630–7. · DOI · Paper page
  54. Nadjarzadeh A, Ghadiri-Anari A, Ramezani-Jolfaie N, Mohammadi M, Salehi-Abargouei A, Namayande SM, et al. Effect of hypocaloric high-protein, low-carbohydrate diet supplemented with fennel on androgenic and anthropometric indices in overweight and obese women with polycystic ovary syndrome: A randomized placebo-controlled trial. Complement Ther Med. 2021;56:102633. · DOI
  55. Moran LJ, Noakes M, Clifton PM, Wittert G, Tomlinson L, Galletly C, et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab. 2004;89(7):3337–44. · DOI · Paper page
  56. González F, Considine RV, Abdelhadi OA, Xue J, Acton AJ. Saturated fat ingestion stimulates proatherogenic inflammation in polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2021;321(5):E689–701. · DOI
  57. González F, Considine RV, Abdelhadi OA, Acton AJ. Oxidative stress in response to saturated fat ingestion is linked to insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(11):5360–71. · DOI · Paper page
  58. Yahay M, Heidari Z, Allameh Z, Amani R. The effects of canola and olive oils consumption compared to sunflower oil, on lipid profile and hepatic steatosis in women with polycystic ovarian syndrome: a randomized controlled trial. Lipids Health Dis. 2021;20(1):1–12. · DOI
  59. Giampaolino P, Foreste V, Di Filippo C, Gallo A, Mercorio A, Serafino P, et al. Microbiome and PCOS: state-of-art and future aspects. Int J Mol Sci. 2021;22(4):2048. · DOI · Paper page
  60. Hou C, Zhang W, Li J, Du L, Lv O, Zhao S, et al. Beneficial Effects of Pomegranate on Lipid Metabolism in Metabolic Disorders. Mol Nutr Food Res. 2019;63(16):e1800773. · DOI
  61. Esmaeilinezhad Z, Babajafari S, Sohrabi Z, Eskandari MH, Amooee S, Barati-Boldaji R. Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: A randomized, triple blind, controlled trial. Nutr Metab Cardiovasc Dis. 2019;29(2):201–8. · DOI
  62. Esmaeilinezhad Z, Barati-Boldaji R, Brett NR, de Zepetnek JOT, Bellissimo N, Babajafari S, et al. The effect of synbiotics pomegranate juice on cardiovascular risk factors in PCOS patients: a randomized, triple-blinded, controlled trial. J Endocrinol Investig. 2020;43(4):539–48. · DOI
  63. Mani UV, Mani I, Biswas M, Kumar SN. An open-label study on the effect of flax seed powder (Linum usitatissimum) supplementation in the management of diabetes mellitus. J Diet Suppl. 2011;8(3):257–65. · DOI
  64. Jacobs DR, Tapsell LC. Food synergy: the key to a healthy diet. Proc Nutr Soc. 2013;72(2):200–6. · DOI · Paper page
  65. Szczuko M, Zapałowska-Chwyć M, Maciejewska D, Drozd A, Starczewski A, Stachowska E. Significant improvement selected mediators of inflammation in phenotypes of women with PCOS after reduction and low GI diet. Mediat Inflamm. 2017;2017:5489523. · DOI
  66. Shele G, Genkil J, Speelman D. A Systematic Review of the Effects of Exercise on Hormones in Women with Polycystic Ovary Syndrome. J Funct Morphol Kinesiol. 2020;5(2):35. · DOI
  67. Patten RK, Boyle RA, Moholdt T, Kiel I, Hopkins WG, Harrison CL, et al. Exercise Interventions in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Front Physiol. 2020;11:606. · DOI · Paper page
  68. dos Santos IK, Ashe MC, Cobucci RN, Soares GM, de Oliveira Maranhão TM, Dantas PMS. The effect of exercise as an intervention for women with polycystic ovary syndrome: A systematic review and meta-analysis. Medicine. 2020;99(16):e19644. · DOI
  69. dos Santos IK, Nunes F, Queiros VS, Cobucci RN, Dantas PB, Soares GM, et al. Effect of high-intensity interval training on metabolic parameters in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2021;16(1):e0245023. · DOI
  70. Richards CT, Meah VL, James PE, Rees DA, Lord RN. HIIT'ing or MISS'ing the Optimal Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of High-Versus Moderate-Intensity Exercise Prescription. Front Physiol. 2021;12:715881. · DOI
  71. Spahn JM, Reeves RS, Keim KS, Laquatra I, Kellogg M, Jortberg B, et al. State of the evidence regarding behavior change theories and strategies in nutrition counseling to facilitate health and food behavior change. J Am Diet Assoc. 2010;110(6):879–91. · DOI · Paper page
  72. Saelens BE, Gehrman CA, Sallis JF, Calfas KJ, Sarkin JA, Caparosa S. Use of self-management strategies in a 2-year cognitive-behavioral intervention to promote physical activity. Behav Ther. 2000;31(2):365–79. · DOI
  73. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril. 2004;82(2):421–9. · DOI · Paper page
  74. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93(11):4299–306. · DOI · Paper page
  75. Geier L, Bekx M, Connor E. Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2012;25(6):367–70. · DOI
  76. Pirotta S, Joham AJ, Moran LJ, Skouteris H, Lim SS. Implementation of evidence-based PCOS lifestyle management guidelines: Perceived barriers and facilitators by consumers using the Theoretical Domains Framework and COM-B Model. Patient Educ Couns. 2021;104(8):2080–8. · DOI
  77. Oberg E, Lundell C, Blomberg L, Gidlöf SB, Egnell PT, Hirschberg AL. Psychological well-being and personality in relation to weight loss following behavioral modification intervention in obese women with polycystic ovary syndrome: a randomized controlled trial. Eur J Endocrinol. 2020;183(1):1–11. · DOI
  78. Larsson I, Hulthén L, Landén M, Pålsson E, Janson P, Stener-Victorin E. Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome. Clin Nutr. 2016;35(1):213–8. · DOI · Paper page
  79. Alvarez-Blasco F, Luque-Ramírez M, Escobar-Morreale HF. Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome. Gynecol Endocrinol. 2011;27(12):978–81. · DOI
  80. de Angelis C, Nardone A, Garifalos F, Pivonello C, Sansone A, Conforti A, et al. Smoke, alcohol and drug addiction and female fertility. Reprod Biol Endocrinol. 2020;18(1):1–26. · DOI · Paper page
  81. Mikkelsen EM, Riis AH, Wise LA, Hatch EE, Rothman KJ, Cueto HT, et al. Alcohol consumption and fecundability: prospective Danish cohort study. BMJ. 2016;354:i4262. · DOI
  82. Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Caffeinated and alcoholic beverage intake in relation to ovulatory disorder infertility. Epidemiology (Cambridge, Mass). 2009;20(3):374. · DOI
  83. Grodstein F, Goldman MB, Cramer DW. Infertility in women and moderate alcohol use. Am J Public Health. 1994;84(9):1429–32. · DOI · Paper page
  84. Mo L, Mansfield DR, Joham A, Cain SW, Bennett C, Blumfield M, et al. Sleep disturbances in women with and without polycystic ovary syndrome in an Australian National cohort. Clin Endocrinol. 2019;90(4):570–8. · DOI · Paper page
  85. Legro RS, Chen G, Kunselman AR, Schlaff WD, Diamond MP, Coutifaris C, et al. Smoking in infertile women with polycystic ovary syndrome: baseline validation of self-report and effects on phenotype. Hum Reprod. 2014;29(12):2680–6. · DOI
  86. Zhang B, Zhou W, Shi Y, Zhang J, Cui L, Chen Z-J. Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome. BMC Endocr Disord. 2020;20(1):1–7. · DOI
  87. Tao Y, Liu B, Chen Y, Hu Y, Zhu R, Ye D, et al. Genetically Predicted Cigarette Smoking in Relation to Risk of Polycystic Ovary Syndrome. Clin Epidemiol. 2021;13:527. · DOI
  88. Cupisti S, Häberle L, Dittrich R, Oppelt PG, Reissmann C, Kronawitter D, et al. Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance. Fertil Steril. 2010;94(2):673–7. · DOI
  89. Xirofotos D, Trakakis E, Peppa M, Chrelias C, Panagopoulos P, Christodoulaki C, et al. The amount and duration of smoking is associated with aggravation of hormone and biochemical profile in women with PCOS. Gynecol Endocrinol. 2016;32(2):143–6. · DOI
  90. Waylen A, Metwally M, Jones G, Wilkinson A, Ledger W. Effects of cigarette smoking upon clinical outcomes of assisted reproduction: a meta-analysis. Hum Reprod Update. 2009;15(1):31–44. · DOI · Paper page
  91. Alur-Gupta S, Lee I, Chemerinski A, Liu C, Lipson J, Allison K, et al. Racial differences in anxiety, depression, and quality of life in women with polycystic ovary syndrome. F S Rep. 2021;2(2):230–7.
  92. Khan NN, Vincent A, Boyle JA, Burggraf M, Pillay M, Teede H, et al. Development of a question prompt list for women with polycystic ovary syndrome. Fertil Steril. 2018;110(3):514–22. · DOI
  93. Roessler KK, Glintborg D, Ravn P, Birkebaek C, Andersen M. Supportive relationships-psychological effects of group counselling in women with polycystic ovary syndrome (PCOS). Commun Med. 2012;9(2):125. · DOI
  94. Abdollahi L, Mirghafourvand M, Babapour JK, Mohammadi M. Effectiveness of cognitive-behavioral therapy (CBT) in improving the quality of life and psychological fatigue in women with polycystic ovarian syndrome: a randomized controlled clinical trial. J Psychosom Obstet Gynecol. 2019;40(4):283–93. · DOI
  95. Raja-Khan N, Agito K, Shah J, Stetter CM, Gustafson TS, Socolow H, et al. Mindfulness-based stress reduction for overweight/obese women with and without polycystic ovary syndrome: design and methods of a pilot randomized controlled trial. Contemp Clin Trial. 2015;41:287–97. · DOI
  96. Stefanaki C, Bacopoulou F, Livadas S, Kandaraki A, Karachalios A, Chrousos GP, et al. Impact of a mindfulness stress management program on stress, anxiety, depression and quality of life in women with polycystic ovary syndrome: a randomized controlled trial. Stress. 2015;18(1):57–66. · DOI
  97. Young CC, Monge M, Minami H, Rew L, Conroy H, Peretz C, et al. Outcomes of a Mindfulness-Based Healthy Lifestyle Intervention for Adolescents and Young Adults with Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol. 2021;35:305–13. · DOI
  98. Jiskoot G, Timman R, Beerthuizen A, Dietz de Loos A, Busschbach J, Laven J. Weight reduction through a cognitive behavioral therapy lifestyle intervention in PCOS: the primary outcome of a randomized controlled trial. Obesity. 2020;28(11):2134–41. · DOI · Paper page
  99. Roessler KK, Birkebaek C, Ravn P, Andersen MS, Glintborg D. Effects of exercise and group counselling on body composition and VO 2max in overweight women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2013;92(3):272–7. · DOI · Paper page
  100. Sam S, Ehrmann DA. Pathogenesis and consequences of disordered sleep in PCOS. Clin Med Insights. 2019;13:1179558119871269.
  101. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86(2):517–20.
  102. Ehrmann DA. Metabolic dysfunction in PCOS: relationship to obstructive sleep apnea. Steroids. 2012;77(4):290–4. · DOI
  103. Shreeve N, Cagampang F, Sadek K, Tolhurst M, Houldey A, Hill C, et al. Poor sleep in PCOS; is melatonin the culprit. Hum Reprod. 2013;28(5):1348–53. · DOI · Paper page
  104. Tamura H, Nakamura Y, Korkmaz A, Manchester LC, Tan DX, Sugino N, et al. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril. 2009;92(1):328–43. · DOI · Paper page
  105. Adriaens I, Jacquet P, Cortvrindt R, Janssen K, Smitz J. Melatonin has dose-dependent effects on folliculogenesis, oocyte maturation capacity and steroidogenesis. Toxicology. 2006;228(2-3):333–43. · DOI · Paper page
  106. Wei D, Zhang C, Xie J, Song X, Yin B, Liu Q, et al. Supplementation with low concentrations of melatonin improves nuclear maturation of human oocytes in vitro. J Assist Reprod Genet. 2013;30(7):933–8. · DOI
  107. Sirotkin AV, Schaeffer HJ. Direct regulation of mammalian reproductive organs by serotonin and melatonin. J Endocrinol. 1997;154(1):1–5. · DOI
  108. Hu KL, Ye X, Wang S, Zhang D. Melatonin Application in Assisted Reproductive Technology: A Systematic Review and Meta-Analysis of Randomized Trials. Front Endocrinol (Lausanne). 2020;11:160. · DOI
  109. Tasali E, Van Cauter E, Ehrmann DA. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clin. 2008;3(1):37–46. · DOI
  110. Thannickal A, Brutocao C, Alsawas M, Morrow A, Zaiem F, Murad MH, et al. Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Clin Endocrinol. 2020;92(4):338–49. · DOI
  111. Kahal H, Kyrou I, Tahrani AA, Randeva HS. Obstructive sleep apnoea and polycystic ovary syndrome: a comprehensive review of clinical interactions and underlying pathophysiology. Clin Endocrinol. 2017;87(4):313–9. · DOI
  112. Franik G, Krysta K, Madej P, Gimlewicz-Pięta B, Oślizło B, Trukawka J, et al. Sleep disturbances in women with polycystic ovary syndrome. Gynecol Endocrinol. 2016;32(12):1014–7. · DOI
  113. Kutenaee MA, Amirjani S, Asemi Z, Taghavi S-A, Allan H, Kamalnadian S-N, et al. The impact of depression, self-esteem, and body image on sleep quality in patients with PCOS: a cross-sectional study. Sleep Breath. 2019;1:1–8.
  114. Moran LJ, March WA, Whitrow MJ, Giles LC, Davies MJ, Moore VM. Sleep disturbances in a community-based sample of women with polycystic ovary syndrome. Hum Reprod. 2015;30(2):466–72. · DOI · Paper page
  115. Bennett CJ, Mansfield DR, Mo L, Joham A, Cain SW, Blumfield ML, et al. Sleep disturbances in women with and without polycystic ovary syndrome and their association with lifestyle factors (diet, physical activity and sitting time). Br J Nutr. 2021; Accepted in press. · doi:10.1210/jendso/bvaa046.093
  116. Cappuccio FP, Taggart FM, Kandala NB, Currie A, Peile E, Stranges S, et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep. 2008;31(5):619–26. · DOI · Paper page
  117. Cappuccio FP, Cooper D, D'elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484–92. · DOI · Paper page
  118. Nandalike K, Strauss T, Agarwal C, Coupey SM, Sin S, Rajpathak S, et al. Screening for sleep-disordered breathing and excessive daytime sleepiness in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2011;159(4):591–6. · DOI
  119. Unfer V, Facchinetti F, Orru B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–58. · DOI · Paper page
  120. Montanino Oliva M, Buonomo G, Calcagno M, Unfer V. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J Ovarian Res. 2018;11(1):38. · DOI
  121. Asbaghi O, Ghanavati M, Ashtary-Larky D, Bagheri R, Rezaei Kelishadi M, Nazarian B, et al. Effects of Folic Acid Supplementation on Oxidative Stress Markers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Antioxidants (Basel). 2021;10:6.
  122. Kazerooni T, Asadi N, Dehbashi S, Zolghadri J. Effect of folic acid in women with and without insulin resistance who have hyperhomocysteinemic polycystic ovary syndrome. Int J Gynaecol Obstet. 2008;101(2):156–60. · DOI
  123. Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol. 2007;23(9):505–10. · DOI
  124. Kilicdag EB, Bagis T, Tarim E, Aslan E, Erkanli S, Simsek E, et al. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod. 2005;20(6):1521–8. · DOI
  125. Bahmani F, Karamali M, Shakeri H, Asemi Z. The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial. Clin Endocrinol. 2014;81(4):582–7. · DOI
  126. Asemi Z, Karamali M, Esmaillzadeh A. Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Mol Nutr Food Res. 2014;58(7):1465–73. · DOI
  127. Guo S, Tal R, Jiang H, Yuan T, Liu Y. Vitamin D Supplementation Ameliorates Metabolic Dysfunction in Patients with PCOS: A SystematicReview of RCTs and Insight into the Underlying Mechanism. Int J Endocrinol. 2020;2020:7850816. · DOI
  128. Miao CY, Fang XJ, Chen Y, Zhang Q. Effect of vitamin D supplementation on polycystic ovary syndrome: A meta-analysis. Exp Ther Med. 2020;19(4):2641–9.
  129. Gao H, Li Y, Yan W, Gao F. The Effect of Vitamin D Supplementation on Blood Lipids in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials. Int J Endocrinol. 2021;2021:8849688. · DOI
  130. Cicek N, Eryilmaz OG, Sarikaya E, Gulerman C, Genc Y. Vitamin E effect on controlled ovarian stimulation of unexplained infertile women. J Assist Reprod Genet. 2012;29(4):325–8. · DOI
  131. Izadi A, Ebrahimi S, Shirazi S, Taghizadeh S, Parizad M, Farzadi L, et al. Hormonal and Metabolic Effects of Coenzyme Q10 and/or Vitamin E in Patients With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019;104(2):319–27.
  132. Tarkesh F, Namavar Jahromi B, Hejazi N, Tabatabaee H. Beneficial health effects of Menaquinone-7 on body composition, glycemic indices, lipid profile, and endocrine markers in polycystic ovary syndrome patients. Food Sci Nutr. 2020;8(10):5612–21. · DOI
  133. Oh JS, Ahn MJ, Han CJ, Kim H, Kwon O, Chung HW, et al. Relationship between flavonoids intake and metabolic syndrome in Korean women with polycystic ovary syndrome. J Nutr Health. 2014;47(3):176–85. · DOI
  134. Romualdi D, Constantini B, Campagna G, Lanzone A, Guido M. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study. Fertil Steril. 2008;90(5):1826–33. · DOI
  135. Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum Reprod. 2008;23(7):1602–6. · DOI
  136. Dunning KR, Robker RL. Promoting lipid utilization with l-carnitine to improve oocyte quality. Anim Reprod Sci. 2012;134(1-2):69–75. · DOI
  137. Jamilian H, Jamilian M, Samimi M, Afshar Ebrahimi F, Rahimi M, Bahmani F, et al. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecol Endocrinol. 2017;33(6):442–7. · DOI
  138. Expression of concern: Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial and The effects of fish oil omega-3 fatty acid supplementation on mental health parameters and metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. J Psychosom Obstet Gynaecol. 2020;41(4):I. · DOI
  139. Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfine ID. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010;4(2):359–64. · DOI
  140. Cianci A, Panella M, Fichera M, Falduzzi C, Bartolo M, Caruso S. d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol Endocrinol. 2015;31(6):483–6. · DOI
  141. Guler I, Himmetoglu O, Turp A, Erdem A, Erdem M, Onan MA, et al. Zinc and homocysteine levels in polycystic ovarian syndrome patients with insulin resistance. Biol Trace Elem Res. 2014;158(3):297–304. · DOI
  142. Gedik O, Zileli MS. Effects of hypocalcemia and theophylline on glucose tolerance and insulin release in human beings. Diabetes. 1977;26(9):813–9. · DOI
  143. Jamilian M, Foroozanfard F, Bahmani F, Talaee R, Monavari M, Asemi Z. Effects of Zinc Supplementation on Endocrine Outcomes in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Biol Trace Elem Res. 2016;170(2):271–8. · DOI
  144. Szczuko M, Skowronek M, Zapalowska-Chwyc M, Starczewski A. Quantitative assessment of nutrition in patients with polycystic ovary syndrome (PCOS). Rocz Panstw Zakl Hig. 2016;67(4):419–26.
  145. Shojaeian Z, Sadeghi R, Latifnejad RR. Calcium and vitamin D supplementation effects on metabolic factors, menstrual cycles and follicular responses in women with polycystic ocvary syndrome: A systematic review and meta-analysis. Caspian J Intern Med. 2019;10(4):359–69.
  146. Nasiadek M, Stragierowicz J, Klimczak M, Kilanowicz A. The Role of Zinc in Selected Female Reproductive System Disorders. Nutrients. 2020;12:8. · DOI
  147. Hajizadeh-Sharafabad F, Moludi J, Tutunchi H, Taheri E, Izadi A, Maleki V. Selenium and Polycystic Ovary Syndrome; Current Knowledge and Future Directions: A Systematic Review. Horm Metab Res. 2019;51(5):279–87. · DOI
  148. Fazelian S, Rouhani MH, Bank SS, Amani R. Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis. J Trace Elem Med Biol. 2017;42:92–6. · DOI
  149. Tang XL, Sun Z, Gong L. Chromium supplementation in women with polycystic ovary syndrome: Systematic review and meta-analysis. J Obstet Gynaecol Res. 2018;44(1):134–43. · DOI
  150. Samimi M, Zarezade Mehrizi M, Foroozanfard F, Akbari H, Jamilian M, Ahmadi S, et al. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. 2017;86(4):560–6. · DOI
  151. Shamasbi SG, Ghanbari-Homayi S, Mirghafourvand M. The effect of probiotics, prebiotics, and synbiotics on hormonal and inflammatory indices in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Nutr. 2020;59(2):433–50. · DOI
  152. Pourteymour Fard Tabrizi F, Hajizadeh-Sharafabad F, Vaezi M, Jafari-Vayghan H, Alizadeh M, Maleki V. Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review. J Ovarian Res. 2020;13(1):11. · DOI
  153. Shojaei-Zarghani S, Rafraf M. Resveratrol and markers of polycystic ovary syndrome: a systematic review of animal and clinical studies. Reprod Sci. 2021;26:1–1.
  154. Zhou K, Zhang J, Xu L, Wu T, Lim CE. Chinese herbal medicine for subfertile women with polycystic ovarian syndrome. Cochrane Database Syst Rev. 2016;10(10):Cd007535.
  155. Arentz S, Smith CA, Abbott J, Bensoussan A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. BMC Complement Altern Med. 2017;17(1):500. · DOI
  156. Zhang D-W, Fu M, Gao S-H, Liu J-L. Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med. 2013;2013:636053. · DOI · Paper page
  157. Ghowsi M, Yousofvand N, Moradi S. Effects of Salvia officinalis L. (common sage) leaves tea on insulin resistance, lipid profile, and oxidative stress in rats with polycystic ovary: An experimental study. Avicenna J Phytomed. 2020;10(3):263–72.
  158. Badgujar SB, Patel VV, Bandivdekar AH. Foeniculum vulgare Mill: a review of its botany, phytochemistry, pharmacology, contemporary application, and toxicology. Biomed Res Int. 2014;2014:842674. · DOI · Paper page
  159. Minnetti M, De Alcubierre D, Bonaventura I, Pofi R, Hasenmajer V, Tarsitano MG, et al. Effects of licorice on sex hormones and the reproductive system. Nutrition. 2022;103-104:111727. · DOI
  160. Armanini D, Mattarello MJ, Fiore C, Bonanni G, Scaroni C, Sartorato P, et al. Licorice reduces serum testosterone in healthy women. Steroids. 2004;69(11-12):763–6. · DOI
  161. Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol. 2007;131(1):61–7. · DOI
  162. Sadeghi Ataabadi M, Alaee S, Bagheri MJ, Bahmanpoor S. Role of Essential Oil of Mentha Spicata (Spearmint) in Addressing Reverse Hormonal and Folliculogenesis Disturbances in a Polycystic Ovarian Syndrome in a Rat Model. Adv Pharm Bull. 2017;7(4):651–4. · DOI
  163. Medagama AB. The glycaemic outcomes of Cinnamon, a review of the experimental evidence and clinical trials. Nutr J. 2015;14:108. · DOI · Paper page
  164. Chen Z-T, Chu H-L, Chyau C-C, Chu C-C, Duh P-D. Protective effects of sweet orange (Citrus sinensis) peel and their bioactive compounds on oxidative stress. Food Chem. 2012;135(4):2119–27. · DOI
  165. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008;46(2):409–20. · DOI · Paper page
  166. Ainehchi N, Khaki A, Farshbaf-Khalili A, Hammadeh M, Ouladsahebmadarek E. The Effectiveness of Herbal Mixture Supplements with and without Clomiphene Citrate in Comparison to Clomiphene Citrate on Serum Antioxidants and Glycemic Biomarkers in Women with Polycystic Ovary Syndrome Willing to be Pregnant: A Randomized Clinical Trial. Biomolecules. 2019;9(6):215. · DOI
  167. Stener-Victorin E, Jedel E, Manneras L. Acupuncture in polycystic ovary syndrome: current experimental and clinical evidence. J Neuroendocrinol. 2008;20(3):290–8. · DOI
  168. Stener-Victorin E, Fujisawa S, Kurosawa M. Ovarian blood flow responses to electroacupuncture stimulation depend on estrous cycle and on site and frequency of stimulation in anesthetized rats. J Appl Physiol (1985). 2006;101(1):84–91. · DOI
  169. Wu J, Chen D, Liu N. Effectiveness of acupuncture in polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2020;99(22):e20441. · DOI
  170. Qu F, Wu Y, Hu X-Y, Barry JA, Zhou J, Wang F-F, et al. The effects of acupuncture on polycystic ovary syndrome: A systematic review and meta-analysis. Eur J Integr Med. 2016;8(1):12–8. · DOI
  171. Monro R. Yoga therapy. J Bodyw Mov Ther. 1997;1(4):215–8. · DOI
  172. Thakur D, Saurabh Singh DS, Tripathi DM, Lufang D. Effect of yoga on polycystic ovarian syndrome: A systematic review. J Bodyw Mov Ther. 2021;27:281–6. · DOI
  173. Verma A, Upadhyay V, Saxena V. Effect of Yoga Therapy on Health Outcomes in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Am J Lifestyle Med. 2021;1:15598276211029221.
  174. Mohseni M, Eghbali M, Bahrami H, Dastaran F, Amini L. Yoga Effects on Anthropometric Indices and Polycystic Ovary Syndrome Symptoms in Women Undergoing Infertility Treatment: A Randomized Controlled Clinical Trial. Evid Based Complement Alternat Med. 2021;2021:5564824. · DOI
  175. Jane-Llopis E, Matytsina I. Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug Aalcohol Rev. 2006;25(6):515–36. · DOI · Paper page
  176. Mendelsohn C. Smoking and depression: a review. Aust Fam Physician. 2012;41(5):304–7.
  177. Al Wattar BH, Teede H, Garad R, Franks S, Balen A, Bhide P, et al. Harmonising research outcomes for polycystic ovary syndrome: an international multi-stakeholder core outcome set. Hum Reprod. 2020;35(2):404–12. · DOI
  178. Dong Z, Xu X, Wang C, Cartledge S, Maddison R, Islam SMS. Association of overweight and obesity with obstructive sleep apnoea: a systematic review and meta-analysis. Obes Med. 2020;17:100185. · DOI
  179. Spiegel K, Tasali E, Leproult R, Van Cauter E. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol. 2009;5(5):253–61. · DOI · Paper page
  180. Chaput J-P, St-Onge M-P. Increased food intake by insufficient sleep in humans: are we jumping the gun on the hormonal explanation? Front Endocrinol. 2014;5:116. · DOI
  181. Chaput J-P, Tremblay A. Insufficient sleep as a contributor to weight gain: an update. Curr Obes Rep. 2012;1(4):245–56. · DOI
  182. Weaver MD, Vetter C, Rajaratnam SM, O’Brien CS, Qadri S, Benca RM, et al. Sleep disorders, depression and anxiety are associated with adverse safety outcomes in healthcare workers: A prospective cohort study. J Sleep Res. 2018;27(6):e12722. · DOI · Paper page
  183. Ham OK, Lee BG, Choi E, Choi SJ. Efficacy of cognitive behavioral treatment for insomnia: a randomized controlled trial. West J Nurs Res. 2020;42(12):1104–12. · DOI
  184. Murawski B, Wade L, Plotnikoff RC, Lubans DR, Duncan MJ. A systematic review and meta-analysis of cognitive and behavioral interventions to improve sleep health in adults without sleep disorders. Sleep Med Rev. 2018;40:160–9. · DOI · Paper page
  185. Sharma MP, Andrade C. Behavioral interventions for insomnia: Theory and practice. Indian J Psychiatry. 2012;54(4):359. · DOI
  186. Alesi S, Ee C, Moran LJ, Rao V, Mousa A. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. Advanc Nutr. 2021;13:1243–66. · DOI
  187. Raja-Khan N, Stener-Victorin E, Wu X, Legro RS. The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2011;301(1):E1–E10. · DOI
  188. Jazani AM, Azgomi HND, Azgomi AND, Azgomi RND. A comprehensive review of clinical studies with herbal medicine on polycystic ovary syndrome (PCOS). DARU J Pharm Sci. 2019;27(2):863–77. · DOI
  189. Bargiota A, Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Advanc Endocrinol Metab. 2012;3(1):27–47. · DOI
  190. Thomson P, Jones J, Evans JM, Leslie SL. Factors influencing the use of complementary and alternative medicine and whether patients inform their primary care physician. Complement Ther Med. 2012;20(1-2):45–53. · DOI
  191. Milden SP, Stokols D. Physicians' attitudes and practices regarding complementary and alternative medicine. Behav Med. 2004;30(2):73–84. · DOI
  192. Ge J, Fishman J, Vapiwala N, Li SQ, Desai K, Xie SX, et al. Patient-physician communication about complementary and alternative medicine in a radiation oncology setting. Int J Radiat Oncol Biol Phys. 2013;85(1):e1–6. · doi:10.1016/j.ijrobp.2012.08.018
  193. Berretta M, Rinaldi L, Taibi R, Tralongo P, Fulvi A, Montesarchio V, et al. Physician attitudes and perceptions of complementary and alternative medicine (CAM): a Multicentre Italian study. Front Oncol. 2020;10:594. · DOI
  194. Barraco D, Valencia G, Riba AL, Nareddy S, Draus CB, Schwartz SM. Complementary and alternative medicine (CAM) use patterns and disclosure to physicians in acute coronary syndromes patients. Complement Ther Med. 2005;13(1):34–40. · DOI
  195. Adler SR, Wrubel J, Hughes E, Beinfield H. Patients' interactions with physicians and complementary and alternative medicine practitioners: older women with breast cancer and self-managed health care. Integr Cancer Ther. 2009;8(1):63–70. · DOI
  196. Schiff E, Frenkel M, Shilo M, Levy M, Schachter L, Freifeld Y, et al. Bridging the physician and CAM practitioner communication gap: suggested framework for communication between physicians and CAM practitioners based on a cross professional survey from Israel. Patient Educ Couns. 2011;85(2):188–93. · doi:10.1016/j.pec.2010.08.029
  197. Venkat Narayan K, Gregg E, Engelgau M, Moore B, Thompson T, Williamson D, et al. Translation research for chronic disease: the case of diabetes. Diabetes Care. 2000;23(12):1794–8. · DOI
  198. Hiss RG. The concept of diabetes translation: addressing barriers to widespread adoption of new science into clinical care. Diabetes Care. 2001;24(7):1293–6. · DOI
  199. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM, et al. Central challenges facing the national clinical research enterprise. JAMA. 2003;289(10):1278–87. · DOI · Paper page
  200. Tay CT, Joham AE, Hiam DS, Gadalla MA, Pundir J, Thangaratinam S, et al. Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Clin Endocrinol. 2018;89(5):535–53. · DOI

200 of 201 shown

Cited by

See all 240

Metadata

Authors
Cowan, S., Lim, S., Alycia, C., Pirotta, S., Thomson, R., Gibson-Helm, M., Blackmore, R., Naderpoor, N., Bennett, C., Ee, C., Rao, V., Mousa, A., Alesi, S., & Moran, L.
Venue
BMC Endocrine Disorders
Published
2023-01-16
Volume
23
Issue
1
Pages
14-14
ISSN
1472-6823 (ISSN-L)
OpenAlex
W4316466644
Cited by
240
References
96
FWCI
46.21
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Jacka Foundation of Natural Therapies
  • National Health and Medical Research Council of Australia
  • National Heart Foundation of Australia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. https://app.cochat.ai/papers/10.1186/s12902-022-01208-y
The paper
Cowan, S., Lim, S., Alycia, C., Pirotta, S., Thomson, R., Gibson-Helm, M., Blackmore, R., Naderpoor, N., Bennett, C., Ee, C., Rao, V., Mousa, A., Alesi, S., & Moran, L. (2023). Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-022-01208-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.